Newsletter | August 29, 2019

08.29.19 -- What Can Biosimilar Makers Learn From This Gene Therapy?

Featured Editorial
2019 U.S. State Policy Trends Impacting Pharma Manufacturers
By Stephanie Hoops, Decision Resources Group (DRG)

If the activity happening in state legislatures across the country heralds change at the federal level — and it likely does — pharmaceutical manufacturers ought to buckle their seatbelts.

4 Important Things To Consider Before Developing A Drug Delivery Device
By Michael Song, Ph.D.

This is Part 1 of a two-part article discussing important areas to consider when developing devices for combination products — and why they need to be addressed early in development.

What Can Cell And Gene Efforts Teach Biosimilar Makers?
By Anna Rose Welch, editor, Biosimilar Development

Not only are the issues impacting cell and gene therapies relatable on the biosimilar side, I’m hoping this particular strategy can inspire creative thinking as scrutiny into the buy-and-bill landscape continues to intensify.

Industry Insights
Raw Materials Management: Technology Advancements Improving Transparency And Global Collaboration
E-Book | GE Healthcare Life Sciences

The ultimate goal of the biopharmaceutical industry is to ensure a consistent supply of safe and effective drugs to patients who need them. One key factor in doing so is to address the challenges of raw material sourcing and management.

Improve Large Biomolecule Purification
Bio-Rad Laboratories, Inc.
Connect With Biosimilar Development: